NO179695C - Anvendelse av æomega-[4-(2-pyrimidinyl)-1-piperazinylÅalkylå-1H-azol-derivater for fremstilling av medisinske produkter beregnet til behandling av forstyrrelser i kognitive funksjoner - Google Patents

Anvendelse av æomega-[4-(2-pyrimidinyl)-1-piperazinylÅalkylå-1H-azol-derivater for fremstilling av medisinske produkter beregnet til behandling av forstyrrelser i kognitive funksjoner

Info

Publication number
NO179695C
NO179695C NO920342A NO920342A NO179695C NO 179695 C NO179695 C NO 179695C NO 920342 A NO920342 A NO 920342A NO 920342 A NO920342 A NO 920342A NO 179695 C NO179695 C NO 179695C
Authority
NO
Norway
Prior art keywords
radical
disorders
treatment
aryl
cognitive functions
Prior art date
Application number
NO920342A
Other languages
English (en)
Norwegian (no)
Other versions
NO920342L (no
NO179695B (no
NO920342D0 (no
Inventor
Jordi Frigola-Constansa
Juan Pares-Corominas
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of NO920342D0 publication Critical patent/NO920342D0/no
Publication of NO920342L publication Critical patent/NO920342L/no
Publication of NO179695B publication Critical patent/NO179695B/no
Publication of NO179695C publication Critical patent/NO179695C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO920342A 1991-01-25 1992-01-24 Anvendelse av æomega-[4-(2-pyrimidinyl)-1-piperazinylÅalkylå-1H-azol-derivater for fremstilling av medisinske produkter beregnet til behandling av forstyrrelser i kognitive funksjoner NO179695C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9100861A FR2671972B1 (fr) 1991-01-25 1991-01-25 Utilisation de derives 1-h-azole-(omega-(4-(2-pyrimidinyl)-1-piperazinyl)-alkyl) pour la preparation de medicaments destines au traitement des troubles des fonctions cognitives.

Publications (4)

Publication Number Publication Date
NO920342D0 NO920342D0 (no) 1992-01-24
NO920342L NO920342L (no) 1992-07-27
NO179695B NO179695B (no) 1996-08-26
NO179695C true NO179695C (no) 1996-12-04

Family

ID=9409058

Family Applications (1)

Application Number Title Priority Date Filing Date
NO920342A NO179695C (no) 1991-01-25 1992-01-24 Anvendelse av æomega-[4-(2-pyrimidinyl)-1-piperazinylÅalkylå-1H-azol-derivater for fremstilling av medisinske produkter beregnet til behandling av forstyrrelser i kognitive funksjoner

Country Status (16)

Country Link
US (1) US5182281A (ko)
EP (1) EP0497658B1 (ko)
JP (1) JPH07121865B2 (ko)
KR (1) KR970001655B1 (ko)
AT (1) ATE126227T1 (ko)
AU (1) AU646137B2 (ko)
CA (1) CA2059984A1 (ko)
DE (1) DE69203874T2 (ko)
DK (1) DK0497658T3 (ko)
ES (1) ES2125207B1 (ko)
FR (1) FR2671972B1 (ko)
GR (1) GR3017648T3 (ko)
HU (1) HU214319B (ko)
NO (1) NO179695C (ko)
RU (1) RU2078568C1 (ko)
ZA (1) ZA92504B (ko)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681956A (en) * 1990-12-28 1997-10-28 Neurogen Corporation 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
US5712392A (en) * 1990-12-28 1998-01-27 Neurogen Corporation Certain 4-piperidine- and piperazinoalkyl-2-phenyl imidazole derivatives; dopamine receptor subtype specific ligands
FR2701260B1 (fr) * 1993-02-05 1995-05-05 Esteve Labor Dr Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments.
FR2705098B1 (fr) * 1993-05-10 1995-08-04 Esteve Labor Dr Procédé de préparation de 2-{4-[4-(chloro-1-pyrazolyl)butyl]1-pipérazinyl}pyrimidine (Lesopitron) .
GB9408084D0 (en) * 1994-04-23 1994-06-15 Boots Co Plc Medical treatment
ES2117934B1 (es) * 1994-07-29 1999-04-01 Esteve Labor Dr Tetrahidropiridinas (0 4-hidroxipiperidinas) alquilazoles.
US6355659B1 (en) 1994-07-29 2002-03-12 Laboratorios Del Dr. Esteve, S.A. 4-(4-Chlorophenyl)-1236-tetrahydro-1(1H-124-triazol-1-yl)butty)pyrideine and salts thereof; pharmaceutical compositions and method of treating psychoses utilizing same
FR2723091B1 (fr) * 1994-07-29 1996-11-08 Esteve Labor Dr Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles
ES2099031B1 (es) * 1995-05-31 1997-12-01 Esteve Labor Dr Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen.
US6166205A (en) * 1998-09-02 2000-12-26 Neurogen Corporation 2-Aryl-4-(1-[4-heteroaryl]piperazin-1-yl)methylimidazoles: dopamine . D.sub4 receptor subtype ligands
US8123782B2 (en) * 2004-10-20 2012-02-28 Vertiflex, Inc. Interspinous spacer
US8152837B2 (en) 2004-10-20 2012-04-10 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US9161783B2 (en) 2004-10-20 2015-10-20 Vertiflex, Inc. Interspinous spacer
US8167944B2 (en) 2004-10-20 2012-05-01 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US8128662B2 (en) * 2004-10-20 2012-03-06 Vertiflex, Inc. Minimally invasive tooling for delivery of interspinous spacer
US9023084B2 (en) 2004-10-20 2015-05-05 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for stabilizing the motion or adjusting the position of the spine
US9119680B2 (en) 2004-10-20 2015-09-01 Vertiflex, Inc. Interspinous spacer
US8425559B2 (en) 2004-10-20 2013-04-23 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
US8409282B2 (en) 2004-10-20 2013-04-02 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
US8317864B2 (en) 2004-10-20 2012-11-27 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US8292922B2 (en) 2004-10-20 2012-10-23 Vertiflex, Inc. Interspinous spacer
WO2009009049A2 (en) 2004-10-20 2009-01-15 Vertiflex, Inc. Interspinous spacer
US7763074B2 (en) * 2004-10-20 2010-07-27 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US8123807B2 (en) 2004-10-20 2012-02-28 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
US8613747B2 (en) * 2004-10-20 2013-12-24 Vertiflex, Inc. Spacer insertion instrument
US8277488B2 (en) * 2004-10-20 2012-10-02 Vertiflex, Inc. Interspinous spacer
US8864828B2 (en) * 2004-10-20 2014-10-21 Vertiflex, Inc. Interspinous spacer
US8945183B2 (en) * 2004-10-20 2015-02-03 Vertiflex, Inc. Interspinous process spacer instrument system with deployment indicator
US8012207B2 (en) * 2004-10-20 2011-09-06 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
WO2009086010A2 (en) 2004-12-06 2009-07-09 Vertiflex, Inc. Spacer insertion instrument
US8845726B2 (en) 2006-10-18 2014-09-30 Vertiflex, Inc. Dilator
WO2011084477A2 (en) 2009-12-15 2011-07-14 Vertifex, Inc. Spinal spacer for cervical and other vertebra, and associated systems and methods
US9675303B2 (en) 2013-03-15 2017-06-13 Vertiflex, Inc. Visualization systems, instruments and methods of using the same in spinal decompression procedures
EP3139848A4 (en) 2014-05-07 2018-06-13 Vertiflex, Inc. Spinal nerve decompression systems, dilation systems, and methods of using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2642759B1 (fr) * 1989-02-09 1991-05-17 Laboratorios Esteve Sa Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante
FR2654621B1 (fr) * 1989-11-22 1994-09-23 Esteve Labor Dr Inhibition du syndrome d'abstinence.

Also Published As

Publication number Publication date
NO920342L (no) 1992-07-27
ES2125207B1 (es) 1999-01-01
DK0497658T3 (da) 1995-10-02
AU1044592A (en) 1992-07-30
GR3017648T3 (en) 1996-01-31
HU214319B (hu) 1998-03-02
EP0497658A1 (fr) 1992-08-05
DE69203874T2 (de) 1995-12-07
AU646137B2 (en) 1994-02-10
JPH07121865B2 (ja) 1995-12-25
JPH04312529A (ja) 1992-11-04
HUT60433A (en) 1992-09-28
HU9200232D0 (en) 1992-04-28
ATE126227T1 (de) 1995-08-15
RU2078568C1 (ru) 1997-05-10
DE69203874D1 (de) 1995-09-14
FR2671972A1 (fr) 1992-07-31
EP0497658B1 (fr) 1995-08-09
CA2059984A1 (fr) 1992-07-26
NO179695B (no) 1996-08-26
FR2671972B1 (fr) 1995-03-03
KR920014472A (ko) 1992-08-25
KR970001655B1 (ko) 1997-02-13
US5182281A (en) 1993-01-26
NO920342D0 (no) 1992-01-24
ZA92504B (en) 1992-10-28

Similar Documents

Publication Publication Date Title
NO179695C (no) Anvendelse av æomega-[4-(2-pyrimidinyl)-1-piperazinylÅalkylå-1H-azol-derivater for fremstilling av medisinske produkter beregnet til behandling av forstyrrelser i kognitive funksjoner
HUT68357A (en) Heterocyclic-cyclic-amine derivatives, pharmaceutical compositions containing them and process for their production
PT100620A (pt) Derivados de tetra-hidrocarbazol, seu uso e preparacao e composicoes farmaceuticas que os contem
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
HUP0004564A2 (hu) Gasztrokinetikus hatású 3- vagy 4-szubsztituált 4-(aminometil)-piperidin-származékok monociklusos benzamidjai, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
ATE161723T1 (de) Arzneimittel zur verwendung bei der behandlung von parkinsonismus
DE69216293D1 (de) 1,4-Disubstituierte Piperidinderivate, ihre Herstellung und therapeutische Verwendung
ATE170530T1 (de) Thiazolidinderivate, ihre herstellung und medikamente, die sie enthalten
DK671588D0 (da) Bisphenylalkylpiperazinderivater og fremgangsmaade til fremstilling deraf
NO905028D0 (no) Fremstilling av abstinenssyndromhemmende forbindelser.
ATE73785T1 (de) 5-(3-alkyl-5-tert.butyl-4-hydroxyphenyl)-2-amin - 6h-1,3,4-thiadiazine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung.
DK64191D0 (da) 4-methyl-5-(2-(4-phenyl-1-piperazinyl)ethyl)thiazolderivater og fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende thiazolderivaterne
NZ244420A (en) Imidazolylmethyl-pyridine derivatives and pharmaceutical compositions
ES2009689A6 (es) Procedimiento para preparar derivados de 3-piperidina-carbaldehido-oxima.
DE69017265T2 (de) Pyrrolidonderivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel.
ATE79752T1 (de) Verwendung von chromanderivaten zur herstellung eines medikamentes zur behandlung von depressiven zustaenden.
TH9795EX (th) 1-(1h-อิมิดาซอล-4-อิล)อัลคิลเบนซามีตที่ถูกแทนที่

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN JULY 2002